Bone Biologics regains compliance with Nasdaq listing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2025
0mins
Regaining Compliance: Bone Biologics has received confirmation from The Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Continued Listing: The company is now compliant with all applicable listing standards, ensuring its common stock will remain listed on the Nasdaq Capital Market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBLG
About BBLG
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Product Shelf Life Extension: Bone Biologics successfully extended the shelf life of its rhNELL-1 protein product to 24 months, which not only enhances manufacturing efficiency but also improves supply chain flexibility, supporting clinical readiness.
- Strengthened Capital Structure: The company completed a $5 million registered public offering in Q2 2025, providing funding to support ongoing clinical development activities and intellectual property initiatives, ensuring stability in capital markets.
- Intellectual Property Expansion: Bone Biologics filed a U.S. patent application related to its bone regeneration technology, further strengthening its proprietary platform and enhancing long-term value in the competitive landscape.
- Nasdaq Compliance Restored: The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, reinforcing its ability to access public capital markets continuously.
Continue Reading
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Shelf Life Extension: Bone Biologics announces that the shelf life of its rhNELL-1 product has been extended to 24 months, based on ongoing stability data, representing a logical progression from prior 12- and 18-month milestones.
- Manufacturing Efficiency Improvement: The extended shelf life is expected to enhance manufacturing efficiency, inventory management, and supply chain flexibility, thereby supporting clinical and commercial readiness as the company advances product development.
- Accelerated Commercialization: CEO Jeff Frelick states that this milestone is an important step toward commercialization, expected to support disciplined capital deployment and long-term shareholder value creation.
- Bone Regeneration Technology Development: Bone Biologics is developing rhNELL-1 as a differentiated bone growth factor designed to promote bone regeneration in hard-to-heal fusion settings, further solidifying its competitive position in the spinal fusion market.
Continue Reading